Wall Street brokerages predict that MeiraGTx Holdings PLC (NASDAQ:MGTX) will announce earnings of ($0.64) per share for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have issued estimates for MeiraGTx’s earnings. The company is expected to report its next earnings report on Tuesday, June 25th.
According to Zacks, analysts expect that MeiraGTx will report full-year earnings of ($3.50) per share for the current year, with EPS estimates ranging from ($3.97) to ($3.03). For the next financial year, analysts anticipate that the firm will post earnings of ($3.32) per share. Zacks Investment Research’s earnings per share averages are a mean average based on a survey of research analysts that cover MeiraGTx.
MeiraGTx (NASDAQ:MGTX) last issued its quarterly earnings results on Tuesday, March 26th. The company reported ($0.58) EPS for the quarter, topping analysts’ consensus estimates of ($0.63) by $0.05.
In other MeiraGTx news, major shareholder Life Sciences Maste Perceptive bought 1,304,348 shares of the business’s stock in a transaction that occurred on Friday, March 1st. The stock was purchased at an average price of $13.80 per share, for a total transaction of $18,000,002.40. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.
Institutional investors have recently made changes to their positions in the stock. SG Americas Securities LLC bought a new position in MeiraGTx during the fourth quarter valued at approximately $138,000. Geode Capital Management LLC boosted its stake in MeiraGTx by 54.1% during the fourth quarter. Geode Capital Management LLC now owns 16,625 shares of the company’s stock valued at $160,000 after buying an additional 5,834 shares during the last quarter. Prosight Management LP bought a new position in MeiraGTx during the third quarter valued at approximately $527,000. Northern Trust Corp boosted its stake in MeiraGTx by 51.7% during the fourth quarter. Northern Trust Corp now owns 40,913 shares of the company’s stock valued at $395,000 after buying an additional 13,936 shares during the last quarter. Finally, Sphera Funds Management LTD. bought a new position in MeiraGTx during the fourth quarter valued at approximately $686,000. 26.37% of the stock is owned by institutional investors.
Shares of NASDAQ:MGTX traded down $0.56 during trading on Friday, hitting $17.23. 156,280 shares of the company’s stock were exchanged, compared to its average volume of 248,268. MeiraGTx has a 52-week low of $7.98 and a 52-week high of $21.93. The stock has a market capitalization of $571.76 million and a P/E ratio of -3.92.
MeiraGTx Company Profile
MeiraGTx Holdings plc, an integrated clinical stage gene therapy company, develops various gene therapy products for the lives of patients suffering from acquired and inherited disorders. The company focuses on various areas of unmet medical need comprising inherited retinal diseases, xerostomia, and neurodegenerative diseases.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for MeiraGTx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MeiraGTx and related companies with MarketBeat.com's FREE daily email newsletter.